B-Cell Non-Hodgkins Lymphoma Market 2024: Opportunity Analysis and Forecasts
"The
Latest Research Report OpportunityAnalyzer: B-Cell Non-Hodgkins
Lymphoma (NHL) - Opportunity Analysis and Forecasts to 2024 provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
About
B-Cell Non-Hodgkins Lymphoma Market
Non-Hodgkins lymphoma (NHL)
comprises a heterogeneous group of lymphoproliferative malignancies
that arise in the B cells, T cells, or natural killer (NK) cells
within the lymphoid tissue, such as the lymph nodes, bone marrow,
thymus, and spleen. NHLs are further categorized into indolent or
aggressive prognostic subtypes, which further influence the outcomes
and treatment decisions. Patients diagnosed with indolent NHLs
(follicular lymphoma [FL] or marginal zone lymphoma [MZL]) can
achieve a median survival of 10 to 20 years, and relative 10-year
survival rates of over 60%. However, patients with aggressive NHLs
(diffuse large B-cell lymphoma [DLBCL] or mantle cell lymphoma [MCL])
can generally expect lower median survival rates, with the relative
10-year survival reported to be less than 50%.
For the purposes of this report,
GlobalData focuses on the four most prevalent B-cell NHL subtypes:
FL, MZL, DLBCL and MCL. The global market is defined to include sales
of drugs aimed at treatment of those four subtypes in patients 30
years and older across the 7MM, which is comprised of the US, 5EU
(France, Germany, Italy, Spain, and the UK), and Japan. The forecast
includes the sale of agents in first-line, relapsed/refractory, and
maintenance settings. GlobalData anticipates a major driver of market
growth to be the steady increase in uptake of Imbruvica to treat MCL,
and its anticipated expansion into FL, MZL, and DLBCL treatment
settings over the forecast period.
Highlights
Key Questions Answered
- Based on interviews with key
opinion leaders (KOLs), GlobalData has identified the major unmet
needs in the NHL marketplace. Will the leading pipeline agents fulfil
these unmet needs during the forecast period (2014-2024)?
- What research and development
(R&D) strategies will companies leverage to compete in the future
NHL marketplace?
- Which pipeline products are
poised to make a major clinical and commercial impact?
- What clinical and commercial
factors are likely to influence NHL drug uptake in the US and 5EU
(France, Germany, Italy, Spain, and the UK) and Japan (7MM)?
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/699478
Key Findings
- GlobalData projects the NHL
market in the 7MM to experience modest growth from approximately
$4.82bn in 2014 to a little under $5.5bn in 2024, at a compound
annual growth rate (CAGR) of 1.0%. This growth will be fueled by the
launch of the premium-priced drug Imbruvica in the DLBCL first-line
and relapsed/refractory settings. In addition Revlimid is expected to
launch in multiple indications across indolent and aggressive NHL,
along with Zydelig, Gazyva, and other novel pipeline products.
- Primary and secondary research
indicates that Imbruvica and Revlimid will experience rapid uptake
due to high KOL enthusiasm and promising clinical efficacy results
reported thus far. Furthermore, the ability to combine these agents
with standard backbone therapies will aid in their uptake.
- GlobalData anticipates the
launch of generic bendamustine and generic lenalidomide, along with
biosimilar rituximab, at various times in the different markets
during the forecast period. The arrival of those products, in
combination with the stringent pricing and reimbursement criteria in
the 5EU, will act as major barriers to global NHL market growth.
Scope
- Overview of NHL, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and
current treatment options.
- Topline NHL drug market revenue
from 2014-2024. Annual cost of therapy (ACOT) and major product sales
in first-line, relapsed/refractory, and maintenance treatment
settings during the forecast period are included.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, opportunities, and R&D strategies for the NHL market.
- Pipeline analysis: comprehensive
data split across different phases, emerging novel trends under
development, synopses of innovative early-stage projects, and
detailed analysis of late-stage pipeline products. An interactive
clinical and commercial analyzer tool is available.
- Analysis of the current and
future market competition in the global NHL market. Insightful review
of the key industry drivers, restraints and challenges. Each trend is
independently researched to provide qualitative analysis of its
implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline.
- Develop business strategies by
understanding the trends shaping and driving the global NHL
therapeutics market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the NHL market in the
future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analyzing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Table of Contents
1 Table of Contents 10
1.1 List of Tables 15
1.2 List of Figures 20
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 22
3 Disease Overview 23
3.1 Etiology and Pathophysiology
24
3.1.1 Pathophysiology of Indolent
and Aggressive B-Cell NHL 24
3.2 Symptoms 28
4 Disease Management 29
4.1 Diagnosis 29
4.2 Diagnostic Classification 30
4.2.1 Follicular Lymphoma 31
4.2.2 Marginal Zone Lymphoma 32
4.2.3 Diffuse Large B-Cell
Lymphoma 32
4.2.4 Mantle Cell Lymphoma 33
4.3 Treatment Overview 33
4.3.1 Follicular Lymphoma 33
4.3.2 Marginal Zone Lymphoma 36
4.3.3 Diffuse Large B-Cell
Lymphoma 38
4.3.4 Mantle Cell Lymphoma 41
Send
An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/699478
5 Epidemiology 44
5.1 Disease Background 44
5.2 Risk Factors and Comorbidities
44
5.3 Global Trends 46
5.3.1 US 47
5.3.2 5EU 48
5.3.3 Japan 51
5.4 Forecast Methodology 51
5.4.1 Sources Used 53
5.4.2 Sources Not Used 56
5.4.3 Forecast Assumptions and
Methods 56
5.5 Epidemiological Forecast for
B-Cell NHL (2014-2024) 60
5.5.1 Follicular Lymphoma 60
5.5.2 Marginal Zone Lymphoma 67
5.5.3 Diffuse Large B-Cell
Lymphoma 74
5.5.4 Mantle Cell Lymphoma 81
5.6 Discussion 88
5.6.1 Epidemiological Forecast
Insight 88
5.6.2 Limitations of the Analysis
89
5.6.3 Strengths of the Analysis 90
6 Current Treatment Options 91
6.1 Overview 91
6.2 Product Profiles - Major
Brands 93
6.2.1 Imbruvica (ibrutinib) 93
6.2.2 Revlimid (lenalidomide) 101
6.2.3 Rituxan (rituximab) 107
6.2.4 Treanda (bendamustine) 112
6.2.5 Velcade (bortezomib) 116
6.2.6 Zevalin (ibritumomab
tiuxetan) 120
6.2.7 Zydelig (idelalisib,
GS-1101, CAL-101) 124
7 Unmet Needs Assessment and
Opportunity Analysis 129
7.1 Overview 129
7.2 Unmet Needs Analysis 130
7.2.1 Unmet Need: Therapies That
Prolong OS or PFS and Delay Relapse in Indolent NHL Patients 130
7.2.2 Unmet Need: Safe and More
Tolerable Front-Line Agents for Indolent NHL Patients 131
7.2.3 Unmet Need: Prolonged
Survival Rates for MCL Patients 132
7.2.4 Unmet Need: Improved Cure
Rate and Survival for DLBCL Patients after Front-Line Therapy 133
7.2.5 Unmet Need: Predictive and
Prognostic Molecular Biomarkers 134
7.3 Opportunity Analysis 136
7.3.1 Opportunity: More
Cost-Effective Therapies 136
7.3.2 Opportunity: Improved
Consolidation/Maintenance Therapies for Follicular NHL Patients 137
7.3.3 Opportunity: Novel Agents
for Front-Line DLBCL and MCL Therapy 137
7.3.4 Opportunity: Development of
Novel Therapies for NHL Patients 138
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment